Health Condition 1: O268- Other specified pregnancy relatedconditions
Conditions
Interventions
Intervention1: Autologous platelet derived growth factors: Collection of Blood samples,processing sample for autologous platelet derived growth factor preparation,intrauterine administration of autolo
Sponsors
Seragen Biotherapeutics private Limited
Eligibility
Inclusion criteria
Inclusion criteria: Thin endometrium, Two failed implantation in previous IVF cycles
Exclusion criteria
Exclusion criteria: Patient on hormone therapy, Diagnosis of cancer or Chemotherapy treatments,Abnormal platelet function, Previous Incision in the uterus, Endocrine abnormalities such as hyperprolactinemia or abnormal thyroid functions, Systemic use of corticosteroids two weeks before the procedure,Serious, pre-existing medical conditions such as bleeding disorders, septicemia, TB, Acute and chronic infections,Severe metabolic and systemic disorders,Chronic Liver Pathology,Anti-coagulation therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in thickness of endometrium along with improved blood supply to endometrium; increase in endometrial receptivityTimepoint: First dose will be administered on the 5-6th day of menstrual cycle and the second dose will be administered 5 days after the first dose and third dose will be administered 48 hours/2 days before embryo transfer. The endometrium lining will be recorded before each dose. | — |
Secondary
| Measure | Time frame |
|---|---|
| To determine clinical pregnancy rateTimepoint: 2 year | — |
Countries
India
Contacts
Public ContactDr Vasundhara Paliwal
Seragen Biotherapeutics Private Limited
Outcome results
None listed